Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers.

Molecular cancer - 10 Apr 2026

Yan Man, Liu Kai, Xu Jing, Liu Yandi, Ji Liechen, Zhang Shiwu

Abstract excerpt

KRAS is a critical proto-oncogene that encodes a protein functioning as a pivotal molecular switch in intracellular signaling. Both KRAS mutations and MYC dysregulation are key drivers of tumor progression and have historically been regarded as “undruggable” targets. Emerging evidence underscores that the coordinated activation of KRAS and MYC cooperatively fuels tumorigenesis, suggesting that dual inhibition of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Expression Regulation, Neoplastic
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-myc

Share to Proto-Oncogene Proteins p21(ras)

Share to Signal Transduction

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 41964004
DOI: 10.1186/s12943-026-02659-w
PMCID: PMC13196241

Genes

KRAS
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers.PMID 41964004Read ↗

MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancerSemantic proximity Read ↗

KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance.Semantic proximity Read ↗

Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.Semantic proximity Read ↗

Mechanistic Foundations of KRAS‐Driven Tumor Ecosystems: Integrating Crosstalk among Immune, Metabolic, Microbial, and Stromal MicroenvironmentSemantic proximity Read ↗

Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.Semantic proximity Read ↗

Immune modulatory effects of oncogenic KRAS in cancerSemantic proximity Read ↗

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.Semantic proximity Read ↗

KRAS G12C inhibition and innate immune targeting.Semantic proximity Read ↗

KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and RestrictionsSemantic proximity Read ↗

Drugging KRAS: current perspectives and state-of-art review.Semantic proximity Read ↗

KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of ImmunotherapySemantic proximity Read ↗

Targeting KRAS mutant cancers: from druggable therapy to drug resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.